OBEZİTE VE PULMONER EMBOLİZM

Authors

Şule Çilekar

Synopsis

This section examines the effects of obesity, associated with increasing prevalence and high Body Mass Index (BMI), on pulmonary embolism (PE) and venous thromboembolism (VTE), along with diagnostic methods and treatment approaches. In line with Virchow's triad, stasis, endothelial injury, and hypercoagulability play key roles in pathophysiology; elevated fibrinogen, Factor VII, VIII levels, venous stasis, and chronic inflammation significantly increase PE risk in obesity. Course with hemodynamic impairment and right ventricular failure, PE is classified as massive, submassive, and low-risk. Diagnosis utilizes symptoms like pleuritic chest pain and dyspnea, Wells and PESI scoring, D-Dimer testing, Doppler ultrasonography, echocardiography showing McConnell's sign, gold-standard CT pulmonary angiography, and V/Q scintigraphy. Treatment involves low-molecular-weight heparin (LMWH), unfractionated heparin, oral anticoagulants, systemic thrombolytics like tPA in massive cases, and inferior vena cava (IVC) filters when anticoagulation is contraindicated.

References

Moldket AH, Serdula MK, Dietz WH, Bowman BA, Ma JS, Koplan JP. The spread of the obesity epidemic in United States, 1991–1998. JAMA 1999;282:1519–22.

McGee DL. Body mass index and mortality: a meta-analysis based on personlevel data from twenty-six observational studies. Ann Epidemiol 2005;15:87-97

Eno-Obong Essien, MDa, Parth Rali, MDb, Stephen C. Mathai, MD, MHSc. Pulmonary Embolism Med Clin N Am 103 (2019) 549–564

Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19–25.

Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 1999;159:445–53.

Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008;143(2):180–90.

Burrowes KS, Clark AR, Wilsher ML, et al. Hypoxic pulmonary vasoconstriction as a contributor to response in acute pulmonary embolism. Ann Biomed Eng 2014. https://doi.org/10.1007/s10439-014-1011-y.

Mizera R. Pathophysiology of development of pulmonary hypertension after acute pulmonary embolism. Cesk Fysiol 2012;61(1):4–8 [in Czech].

Delcroix M, Melot C, Vermeulen F, et al. Hypoxic pulmonary vasoconstriction and gas exchange in acute canine pulmonary embolism. J Appl Physiol 1996;80(4): 1240–8.

Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submass pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboe bolic pulmonary hypertension: a scientific statement from the american heart sociation. Circulation 2011. https://doi.org/10.1161/CIR.0b013e318214914f

Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test? Vasc Med 2018;23(4):388–99.

Pollack CV, Schreiber D, Goldhaber SZ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: Initial report of EMPEROR (multicenter emergency medicine pulmonary embolism in the real world registry). J Am Coll Cardiol 2011. https://doi.org/10.1016/j.jacc.2010.05.071.

Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010; 56(1):1–7

Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe - The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007. https://doi.org/10.1160/TH07-03-0212.

Sardi A, Gluskin J, Guttentag A, et al. Saddle pulmonary embolism: Is it as bad as it looks? A community hospital experience. Crit Care Med 2011. https://doi.org/ 10.1097/CCM.0b013e31822571b2.

Ambesh P, Obiagwu C, Shetty V. Homan’s sign for deep vein thrombosis: a grain of salt? Indian Heart J 2017;69(3):418–9

Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172(8):1041–6.

Aujesky D. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J

Jime´nez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest 2007; 132(1):24–30.

Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014;311(11):1117–24 2005;27(4):476–81.

Fields JM, Davis J, Girson L, et al. Transthoracic echocardiography for diagnosing pulmonary embolism: a systematic review and meta-analysis. J Am Soc Echocardiogr 2017;30(7):714–23.e4.

Khemasuwan D, Yingchoncharoen T, Tunsupon P, et al. Right ventricular echocardiographic parameters are associated with mortality after acute pulmonary embolism. J Am Soc Echocardiogr 2015;28(3):355–62.

Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006;354:2317–27. Available at: www. nejm.org.

Moores LK, Jackson WL, Shorr AF, et al. Meta-analysis: outcomes in patients with suspected pulmonary embolism managed with computed tomographic pulmonary angiography. Ann Intern Med 2004;141(11):866–74. Available at: www. annals.org.

Hitchen S, James J, Thachil J. Ventilation perfusion scan or computed tomography pulmonary angiography for the detection of pulmonary embolism? Eur J Intern Med 2016;32:e26–7.

Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48(5):680–4.

Findik S, Erkan ML, Selcuk MB, et al. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration 2002;69(5):440–4.

Kabrhel C, Rosovsky R, Channick R, et al. A multidisciplinary pulmonary embolism response team. Chest 2016;150(2):384–93.

Torbicki A, Linhart A, Spyropoulos AC, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014;35(43):3033–69k.

Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014. https://doi.org/10.1056/NEJMoa1302097

Rali PM, Criner GJ. Submassive pulmonary embolism. Am J Respir Crit Care Med 2018. https://doi.org/10.1164/rccm.201711-2302CI.

Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016. https://doi. org/10.1056/ /NEJMoa1601747.

PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Pulmonary Embolism Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005. https://doi.org/10.1161/CIRCULATIONAHA.104.512834

Rosovsky R, Borges J, Kabrhel C, et al. Pulmonary embolism response team: inpatient structure, outpatient follow-up, and is it the current standard of care? Clin Chest Med 2018;39(3):621–30.

Stein PD, Matta F, Goldman J. Obesity and pulmonary embolism: the mounting evidence of risk and the mortality paradox. Thromb Res 2011;128:518–23.

Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182–9.

Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415–20.

Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493–8.

Vaya A, Martinez-Triguero ML, Espana F, et al. The metabolic syndrome and its individual components: its association with venous thromboembolism in a Mediterranean population. Metab Syndr Relat Disord 2011;9:197–201

Friedman SE, Andrus BW. Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms. J. Obes. 2012; 505274. https://doi.org/10.1155/2012/505274

Delluc A, Le Moigne E, Tromeur C, et al. Site of venous thromboembolism and prothrombotic mutations according to body mass index. Results from the EDITH study. Br J Haematol 2011; 154: 486–491.

Drife J. Deep venous thrombosis and pulmonary embolism in obese women. Best Pract Res Clin Obstet Gynaecol 2015; 29: 365–376.

Egermayer P. Obesity, oral contraceptives, and fatal pulmonary embolism. N Z Med J 2001; 114: 170–171.

Sundell IB, Nilsson TK, Ranby M, et al. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjo, Sweden. J Clin Epidemiol 1989; 42: 719–723.

Jimenez S, Ruiz-Artacho P, Merlo M, et al. Risk profile, management, and outcomes of patients with venous thromboembolism attended in Spanish emergency departments: the ESPHERIA registry. Medicine 2017; 96: e8796.

Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.LancetHaematol2019;6:e359-e365.

Published

May 11, 2021

License

License